Maynard Um
-
-
-
-
-
-
-
Cardiol publishes phase II study results in ESC Heart Failure journal
-
-
-
-
-
-
-
Cardiol Therapeutics reaches 50% enrollment in phase III pericarditis trial
-
-
-
-
-
-
-
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
-
-
-
-
-
-
-
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
-
-
-
-
-
-
-
Cardiol Therapeutics (CRDL) Announces Publication of Research in the Journal of the American College of Cardiology
-
-
-
-
-
-
-
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
-
396,354 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

